Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005126501> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2005126501 endingPage "164" @default.
- W2005126501 startingPage "158" @default.
- W2005126501 abstract "Background: Subacute noncardiogenic pulmonary edema is known to be a side effect of high- or intermediate-dose cytosine arabinoside (Ara-C) therapy. This often fatal complication seems to be underestimated, since only few publications concerning this subject are available and clinical and radiographic findings are nonspecific. Patients and Methods: Incidence, clinical course, predisposing factors, and treatment results of pulmonary side effects related to Ara-C therapy were analyzed retrospectively in 89 patients who were treated with a total of 115 therapeutical courses of high-dose ( > 15 g/m2/course) or intermediate-dose (6-15 g/m2/course) Ara-C. Therapy was administered in combination with mitoxantrone (108/115), etoposide (4/115) or daunorubicin (3/115) for treatment of acute myelogenous leukemia (62), acute lymphoblastic leukemia (19), blast crises of chronic myelogenous leukemia (3), or high-grade non-Hodgkin’s lymphoma (5). Results: Pulmonary toxicity attributable to Ara-C therapy was observed in 7 of 115 courses (6%) and appeared 2-18 (median: 10) days after the start of treatment. Three of the affected patients died as a result of respiratory failure and 4 recovered completely. In contrast to the patients who had a lethal course, all patients who recovered had received intravenous corticosteroids at an early stage. Additionally, patients presenting with drug-induced pulmonary toxicity showed considerably more cutaneous reactions related to Ara-C administration (3/7 patients) than the patients without pulmonary toxicity (7/82 patients). Other predisposing factors for the development of pulmonary toxicity were not evaluable. Conclusion: Patients with a history of cutaneous reactions related to Ara-C therapy should be monitored carefully for drug-induced pulmonary toxicity after high-or intermediate-dose Ara-C treatment. If drug-induced pulmonary toxicity is suspected, and other possible underlying causes of the pulmonary changes are excluded, corticosteroid treatment should be started immediately." @default.
- W2005126501 created "2016-06-24" @default.
- W2005126501 creator A5008433641 @default.
- W2005126501 creator A5013171926 @default.
- W2005126501 creator A5052479430 @default.
- W2005126501 creator A5080860389 @default.
- W2005126501 creator A5087543339 @default.
- W2005126501 date "1994-01-01" @default.
- W2005126501 modified "2023-09-26" @default.
- W2005126501 title "Pulmonary Toxicity of Highland Intermediate-Dose Cytosine Arabinoside Therapy: A Retrospective Analysis" @default.
- W2005126501 doi "https://doi.org/10.1159/000218402" @default.
- W2005126501 hasPublicationYear "1994" @default.
- W2005126501 type Work @default.
- W2005126501 sameAs 2005126501 @default.
- W2005126501 citedByCount "0" @default.
- W2005126501 crossrefType "journal-article" @default.
- W2005126501 hasAuthorship W2005126501A5008433641 @default.
- W2005126501 hasAuthorship W2005126501A5013171926 @default.
- W2005126501 hasAuthorship W2005126501A5052479430 @default.
- W2005126501 hasAuthorship W2005126501A5080860389 @default.
- W2005126501 hasAuthorship W2005126501A5087543339 @default.
- W2005126501 hasConcept C126322002 @default.
- W2005126501 hasConcept C141071460 @default.
- W2005126501 hasConcept C2776694085 @default.
- W2005126501 hasConcept C2778119113 @default.
- W2005126501 hasConcept C2778461978 @default.
- W2005126501 hasConcept C2780923524 @default.
- W2005126501 hasConcept C2781047374 @default.
- W2005126501 hasConcept C29730261 @default.
- W2005126501 hasConcept C71924100 @default.
- W2005126501 hasConcept C90924648 @default.
- W2005126501 hasConceptScore W2005126501C126322002 @default.
- W2005126501 hasConceptScore W2005126501C141071460 @default.
- W2005126501 hasConceptScore W2005126501C2776694085 @default.
- W2005126501 hasConceptScore W2005126501C2778119113 @default.
- W2005126501 hasConceptScore W2005126501C2778461978 @default.
- W2005126501 hasConceptScore W2005126501C2780923524 @default.
- W2005126501 hasConceptScore W2005126501C2781047374 @default.
- W2005126501 hasConceptScore W2005126501C29730261 @default.
- W2005126501 hasConceptScore W2005126501C71924100 @default.
- W2005126501 hasConceptScore W2005126501C90924648 @default.
- W2005126501 hasIssue "2" @default.
- W2005126501 hasLocation W20051265011 @default.
- W2005126501 hasOpenAccess W2005126501 @default.
- W2005126501 hasPrimaryLocation W20051265011 @default.
- W2005126501 hasRelatedWork W1976396371 @default.
- W2005126501 hasRelatedWork W1996596930 @default.
- W2005126501 hasRelatedWork W2003295549 @default.
- W2005126501 hasRelatedWork W2017543985 @default.
- W2005126501 hasRelatedWork W2025474481 @default.
- W2005126501 hasRelatedWork W2065399574 @default.
- W2005126501 hasRelatedWork W2076411732 @default.
- W2005126501 hasRelatedWork W2134237771 @default.
- W2005126501 hasRelatedWork W2350876391 @default.
- W2005126501 hasRelatedWork W2426463418 @default.
- W2005126501 hasVolume "17" @default.
- W2005126501 isParatext "false" @default.
- W2005126501 isRetracted "false" @default.
- W2005126501 magId "2005126501" @default.
- W2005126501 workType "article" @default.